Alpha Tau Medical (DRTS) financial statements
Net income was -$43M.
Free cash flow was -$33M.
The diluted share count rose 138% over the period (dilution).
Income statement
Fiscal years, from Alpha Tau Medical's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Research and development | $7M | $8M | $11M | $21M | $26M | $27M | $32M |
| Selling, general and admin | $1M | $2M | $2M | $11M | $9M | $9M | $10M |
| Operating income | $8M | -$9M | -$14M | -$32M | -$36M | -$36M | -$42M |
| Interest expense | — | — | — | — | $75,000 | $303,000 | $347,000 |
| Pre-tax income | $8M | -$9M | -$27M | -$34M | -$29M | -$32M | -$43M |
| Income tax | -$146,000 | $158,000 | $7,000 | $20,000 | $16,000 | $6,000 | $121,000 |
| Net income | -$8M | -$9M | -$27M | -$34M | -$29M | -$32M | -$43M |
| EPS (diluted) | -$0.25 | -$0.22 | -$0.67 | -$0.53 | -$0.42 | -$0.45 | -$0.53 |
| Diluted shares | 34M | 40M | 41M | 64M | 69M | 70M | 81M |
Balance sheet
Fiscal years, from Alpha Tau Medical's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $2M | $16M | $31M | $105M | $85M | $63M | $77M |
| Total current assets | — | $47M | $33M | $106M | $86M | $64M | $78M |
| Property, plant and equipment | — | $5M | $8M | $7M | $13M | $14M | $20M |
| Total assets | — | $53M | $42M | $120M | $107M | $86M | $106M |
| Total current liabilities | — | $2M | $4M | $4M | $7M | $9M | $11M |
| Total liabilities | — | $7M | $23M | $14M | $23M | $24M | $29M |
| Shareholders' equity | -$193,000 | -$8M | -$35M | $106M | $84M | $63M | $77M |
| Net debt | -$2M | -$16M | -$23M | -$6M | -$13M | -$14M | -$12M |
Cash flow
Fiscal years, from Alpha Tau Medical's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7M | -$7M | -$12M | -$24M | -$18M | -$20M | -$27M |
| Capital spending | $1M | $4M | $3M | $904,000 | $6M | $2M | $6M |
| Free cash flow | -$8M | -$11M | -$15M | -$25M | -$24M | -$22M | -$33M |
| Stock-based compensation | $546,000 | $596,000 | $812,000 | $7M | $8M | $10M | $11M |
| Net borrowing | — | — | — | — | $5M | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for DRTS.
Open DRTS in InvestinglyQuestions
How much free cash flow does Alpha Tau Medical generate?
-$33M in fiscal 2025 (operating cash flow minus capital spending).
From Alpha Tau Medical's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.